Immatics NV (IMTX)

Name: Immatics NV (IMTX) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Immatics NV (IMTX)

Stock Card

$9.75

$0.39 (4.17%)

As on 28-Aug-2026 13:36EDT

Market cap

$1,221 Mln

Revenue (TTM)

$42 Mln

P/E Ratio

P/B Ratio

2.5

Div. Yield

0 %

Value Research Rating

Quality Score

Growth Score

Valuation Score

Momentum Score

Know more

Explore 5 star rated stocks

Immatics NV (IMTX) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 9.35 High: 9.88

52 Week Range

Low: 5.05 High: 12.41

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.5 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

7.2
Debt to Equity

0
Book Value

$--
EPS

$-1.6
Face value

--
Shares outstanding

136,689,977

6 Years Aggregate

CFO

€42.62 Mln

EBITDA

€-234.20 Mln

Net Profit

€-447.07 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Immatics NV (IMTX)	-7.1	13.0	-14.4	80.6	-7.3	-4.2	--
BSE Sensex	-8.8	0.6	1.8	-4.4	6.0	6.6	10.8
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 28-Aug-2026 | #As on 26-Oct-2023

Company	2025	2023	2022	2021
Immatics NV (IMTX)	47.7	20.9	-35.2	24.6
S&P Small-Cap 600	4.0	13.9	-17.4	25.3
BSE Sensex	9.1	18.7	4.4	22.0

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About Immatics NV (IMTX)

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies... with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany. Read more

CEO, MD, Member of Management Board & Executive Director

Dr. Harpreet Singh Ph.D.
CEO, MD, Member of Management Board & Executive Director

Dr. Harpreet Singh Ph.D.
Headquarters

Tübingen
Website

https://www.immatics.com

FAQs for Immatics NV (IMTX)

What is the current share price of Immatics NV (IMTX) Today?

The share price of Immatics NV (IMTX) is $9.75 (NASDAQ) as of 28-Aug-2026 13:36 EDT. Immatics NV (IMTX) has given a return of -7.33% in the last 3 years.

What is the current PB & PE ratio of Immatics NV (IMTX)?

Since, TTM earnings of Immatics NV (IMTX) is negative, P/E ratio is not available.
The P/B ratio of Immatics NV (IMTX) is 2.52 times as on 21-Aug-2026, a 28 discount to its peers’ median range of 3.48 times.

PE & PB ratio at the end of financial year.